Mitapivat significantly boosted hemoglobin in SCD patients over one year, paving the way for potential FDA submission for ...
In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle | ...
Agios Pharmaceuticals, Inc. drops after mixed Phase 3 mitapivat results in Sickle Cell Disease. Click here to find out why ...
Shares in Agios Pharma lost nearly half their value in pre-market trading today after it posted mixed clinical results from a ...
The review discusses hydroxyurea and 3 additional drugs approved by the FDA—L-glutamine, crizanlizumab, and voxelotor—as well as agents currently being investigated to treat sickle cell disease (SCD).
Marissa Johanna Maria Traets Bridging Pathophysiology and Therapeutic Targets in Sickle Cell Disease dr. M.A.E. Rab ...
The Ministry of Health says it now recognises Sickle Cell Disease (SCD) as a public health and developmental challenge that requires a coordinated, multisectoral response, anchored in prevention, earl ...
DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients ...
CHICAGO, December 13, 2023 (Newswire.com) - The American Society for Transplantation and Cellular Therapy® (ASTCT®) recognizes the US Food and Drug Administration's (FDA) recently granted approval for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback